Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.38 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | DRD1 | P21728 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258587 | 0.87 | KCNE1 (0.38) | KCNE1KCNQ1KCNH2ABCC9 | |
| SCHEMBL482380 | 0.82 | ABCC9 (0.52) | KCNE1KCNQ1LMNAHTTABCC9 | |
| SCHEMBL4716582 | 0.82 | ABCC9 (0.52) | KCNE1KCNQ1LMNAHTTABCC9 | |
| SCHEMBL481908 | 0.82 | ABCC9 (0.52) | KCNE1KCNQ1LMNAHTTABCC9 | |
| SCHEMBL5868353 | 0.81 | IDO1 (0.40) | HTR2CHTR1ASLC6A2HTR2B | |
| SCHEMBL6274078 | 0.81 | IDO1 (0.40) | HTR2CHTR1ASLC6A2HTR2B | |
| SCHEMBL5868357 | 0.81 | IDO1 (0.40) | HTR2CHTR1ASLC6A2HTR2B | |
| SCHEMBL8947014 | 0.80 | IDO1 (0.36) | KCNE1KCNQ1 | |
| SCHEMBL8947007 | 0.80 | IDO1 (0.36) | KCNE1KCNQ1 | |
| SCHEMBL8947011 | 0.80 | IDO1 (0.36) | KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0076075-B1 | PHARMACEUTICALLY ACTIVE BENZOPYRAN COMPOUNDS | BEECHAM GROUP PLC (GB) | 1986-11-20 | — | — | EP | claimed |
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
| WO-2003014113-A1 | NOVEL BENZOPYRAN COMPOUNDS AND PROCESS FOR THEIR PREPARATION AND USE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2003-02-20 | — | — | WO | disclosed |
| EP-0076075-B1 | PHARMACEUTICALLY ACTIVE BENZOPYRAN COMPOUNDS | BEECHAM GROUP PLC (GB) | 1986-11-20 | — | — | EP | disclosed |
| US-4610992-A | Trans-4-(2-thiaoxo-1-pyrrolidinyl or piperidinyl)-2H-benzo[b]pyran-3-ol derivatives useful in treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1986-09-09 | — | — | US | disclosed |
| US-4568692-A | LOWERING BLOOD PRESSURE | BEECHAM GROUP P.L.C. | 1986-02-04 | — | — | US | disclosed |
| US-4510152-A | Antihypertensive chromenes and chromans | BEECHAM GROUP P.L.C. (GB) | 1985-04-09 | — | — | US | disclosed |
| US-4481214-A | 4-Acylaminobenzopyrans useful as anti-hypertensive agents | BEECHAM GROUP P.L.C. (GB) | 1984-11-06 | — | — | US | disclosed |
| EP-0120427-A1 | 3,4-Dihydro-thiaoxo-1-pyrrolidinyl-or piperidinyl-ZH-benzo[b]pyrons | BEECHAM GROUP PLC (GB) | 1984-10-03 | — | — | EP | disclosed |
| US-4446113-A | HYPOTENSIVE AGENTS | BEECHAM GROUP P.L.C. (GB) | 1984-05-01 | — | — | US | disclosed |
| EP-0095316-A1 | Pharmaceutically active aminobenzopyrans | BEECHAM GROUP PLC (GB) | 1983-11-30 | — | — | EP | disclosed |
| EP-0093535-A1 | Novel chromenes and chromans | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
| EP-0076075-A1 | Pharmaceutically active benzopyran compounds | BEECHAM GROUP PLC (GB) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | KCNE1 33/4885KCNQ1 15/4885LMNA 1200/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | KCNE1 33/4885KCNQ1 15/4885LMNA 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.